Valuation and view: The third consecutive quarter of high quality Ebitda growth belies the streets concerns on the one-off nature of margin expansion posted in earlier quarters. We like the companys disproportionate focus on driving premium portfolio and rationalisation of low margin/regional SKUs (stock keeping units). We expect gross margins to expand 320 bps over FY13-15e primarily driven by benefits from premiumisation. We are now building in 300 bps operating margin expansion over FY13-15e to 8.8%. Stock has delivered significant outperformance (outperformed BSE FMCG and Sensex by 70% and 66%, respectively, year-to-date) on the back of strong quarterly performance since Q4FY13. We expect the premium valuations to sustain as Britannia reaps the benefits of its premiumisation plus cost containment strategy over the medium term.
Earnings revision: We are revising our estimates upwards by ~15% for FY14e and FY15e to incorporate the H1 beat versus our expectations. We are estimating a 37.4% EPS CAGR (compound annual growth rate) over FY13-FY15e.
Q2FY14 results: Britannia Industries Q2FY14 results were well ahead of our estimates. Adjusted PAT more than doubled and grew 110% to R957m (estimated R768m).
Sales in line with estimates: Stand-alone sales grew 13.7% to R15.94 bn (estimated R15.9 bn); volume growth estimated at 5-6% while realisation and mix improvement contributed the rest. Consolidated sales posted 13% y-o-y growth to R17.4 bn. Subsidiary sales posted a muted 4% y-o-y growth.
Standalone gross margins expand 380bps: Gross margin expanded 380 bps y-o-y to 39.4% driven by premiumisation as well as price hikes. The management had earlier enunciated its strategy of de-focusing on smaller and less profitable SKUs. Other expenses declined 40 bps, adspends declined 20 bps while conversion costs remained flat y-o-y. Thus, Ebitda margins expanded 430 bps y-o-y to 8.6% (estimated 7%) resulting in robust 127% y-o-y growth in Ebitda. Ebitda margins of 8.6% is highest in 16 quarters.
This is third consecutive quarter of solid Ebitda performance belying concerns of any one-off elements. We reiterate that low margin nature of the business lends itself to exaggerated impact on Ebitda either ways due to changes in cost line item. Other income and interest expenses declined 25% and 87%, respectively, driving PBT (profit before tax) growth of 119%. However, tax rates moved up 300 bps y-o-y to 32%. Therefore, Adjusted PAT grew 110% to R957m (estimated R768m). Consolidated Ebitda and PAT grew 93% and 66%, respectively with an underlying 370 bps and 350 bps gross and Ebitda margin expansion. For the first half FY14, standalone sales, Ebitda, and PAT have grown 14%, 102%, and 104% respectively.
Consolidated sales, Ebitda, and PAT have grown 13%, 82%, and 78%, respectively.